TP53 and neoplasm: The WEE1 inhibitor MK‐1775 has demonstrated greater efficacy in p53‐deficient tumour cells when combined with agents such as gemcitabine, carboplatin, cisplatin or 5‐fluorouracil, compared to its use as a monotherapy [74, 75].